PlumX Metrics
Embed PlumX Metrics

Renal Thrombotic Microangiopathy: A Review

American Journal of Kidney Diseases, ISSN: 0272-6386, Vol: 81, Issue: 5, Page: 591-605
2023
  • 43
    Citations
  • 0
    Usage
  • 79
    Captures
  • 5
    Mentions
  • 247
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    43
  • Captures
    79
  • Mentions
    5
    • Blog Mentions
      3
      • Blog
        3
    • News Mentions
      2
      • News
        2
  • Social Media
    247
    • Shares, Likes & Comments
      247
      • Facebook
        247

Most Recent News

Late-onset renal TMA and tubular injury in cobalamin C disease: a report of three cases and literature review

Abstract Background Mutation of MMACHC gene causes cobalamin C disease (cblC), an inherited metabolic disorder, which presents as combined methylmalonic aciduria (MMA-uria) and hyperhomocysteinaemia in clinical.

Review Description

Thrombotic microangiopathy (TMA), a pathological lesion observed in a wide spectrum of diseases, is triggered by endothelial injury and/or dysfunction. Although TMA lesions are often accompanied by clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and ischemic end-organ injury, renal-limited forms of TMA are not infrequently encountered in clinical practice. The presence of renal-limited manifestations can be diagnostically challenging, often delaying the initiation of targeted therapy. Prompt investigation and empirical treatment of TMA is warranted to reduce associated morbidity and mortality. Major advances have been made with respect to the pathophysiology of primary TMA entities, with the subsequent development of novel diagnostic tools and lifesaving therapies for diseases like thrombotic thrombocytopenic purpura and complement-mediated TMA. This article will review the clinical presentation and pathologic hallmarks of TMA involving the kidney, and the disease-specific mechanisms that contribute to the endothelial injury that characterizes TMA lesions. Diagnostic approach and both empirical and disease-specific treatment strategies will be discussed, along with the potential role for emerging targeted disease-specific therapies.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know